GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Summit Therapeutics Inc (MEX:SMMT) » Definitions » Issuance of Stock

Summit Therapeutics (MEX:SMMT) Issuance of Stock : MXN9,135.70 Mil (TTM As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Summit Therapeutics Issuance of Stock?

Summit Therapeutics's Issuance of Stock for the three months ended in Dec. 2024 was MXN-2.19 Mil.

Summit Therapeutics's Issuance of Stock for the trailing twelve months (TTM) ended in Dec. 2024 was MXN9,135.70 Mil.


Summit Therapeutics Issuance of Stock Historical Data

The historical data trend for Summit Therapeutics's Issuance of Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Summit Therapeutics Issuance of Stock Chart

Summit Therapeutics Annual Data
Trend Jan15 Jan16 Jan17 Jan18 Jan19 Dec20 Dec21 Dec22 Dec23 Dec24
Issuance of Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 994.60 1,538.55 1,949.60 1,861.84 9,966.79

Summit Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Issuance of Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 95.38 - 3,664.02 5,473.86 -2.19

Summit Therapeutics Issuance of Stock Calculation

A company may raise cash from issuing new shares. Issuance of Stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Issuance of Stock for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN9,135.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Summit Therapeutics Issuance of Stock Related Terms

Thank you for viewing the detailed overview of Summit Therapeutics's Issuance of Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Summit Therapeutics Business Description

Traded in Other Exchanges
Address
601 Brickell Key Drive, Suite 1000, Miami, FL, USA, 33131
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.